Correction to Lancet Oncol 2019; 20: 1750–59

Park YH, Kim T-Y, Kim GM, et al. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 2019; 20: 1750–59—In this Article, in the Outcomes section of the Methods, it was stated incorrectly that progression-free survival and overall survival were measured from randomisation, whereas they were actually measured from day 1 of cycle 1. This was also incorrect in the Results section and on the x-axis title of figure 2. These corrections have been made to the online version as of Feb 3, 2025.